Provided herein are methods of treating Tourette Syndrome in a subject in need thereof by administering to the subject compositions comprising a PDE10 inhibitor. Also disclosed are crystalline solid forms of the compound of Formula I and uses thereof:

##STR00001##

The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.

The invention is directed to a composition comprising a green tea flower extract and methods for making and using the composition in the management of a healthy body weight. The composition can comprise an aqueous alcohol extract of Camellia sinensis that is administered to a patient to provide a method for maintaining a healthy body weight.

The present invention falls within the general field of cosmetics, and in particular, it relates to a breakable capsule (1) with a membrane (2) and core (3) suitable for releasing an active ingredient comprised in the membrane (2), both for cosmetic use and for pharmaceutical use and to the preparation processes thereof. The capsule (1) has good chemical and mechanical stability wherein the capsule, once applied to the skin, reduces or does not generate residues and, at the same time, any residual trace produced by the membrane (2) can be absorbed or adsorbed by the skin. In addition, they have good stability against light and breakage.

According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

The present invention relates to a pharmaceutical composition comprising topiramate, and more particularly, to a solid pharmaceutical composition comprising topiramate, a cellulose derivative, a lipid and optional pharmaceutical excipients, wherein the weight ratio of topiramate to the cellulose derivative is 100:10 to 100. The pharmaceutical compositions of the present invention have excellent formulation properties as well. The pharmaceutical compositions of the present invention can be used for monotherapy for patients who are newly diagnosed with epilepsy, or patients who have been previously treated with combination therapy and now for monotherapy. They can also be used for the add-on treatment of partial seizures in adults and children aged 2 to 16 years.

PCT Published Abstract

A solid pharmaceutical composition comprising topiramate and a process for the preparation thereof comprising:a topiramate, a cellulose derivative, a lipid and optionally a pharmaceutical adjuvant, wherein the weight ratio of topiramate to the cellulose derivative is 100:10˜100.

A method of forming a dietary supplement can include steps of creating a composition of matter comprising tianeptine, sakae naa, and optionally, at least one of kava, CDP Choline, and Alpha GPC; and providing the composition of matter in a liquid or solid form. The ingredient of tianeptine can be tianeptine sodium, tianeptine free acid, or both. Providing the composition of matter can include filling a container with the composition of matter.

A composite capsule and a method of preparing the same are provided. The composite capsule includes: a raloxifene separate layer including raloxifene or a pharmaceutically acceptable salt thereof; and a vitamin D separate layer including vitamin D or a derivative thereof, wherein the raloxifene separate layer and the vitamin D separate layer are separated from one another in the composite capsule.

The present invention relates to an application of a traditional Chinese medicine composition and formulation thereof in the preparation of medicaments for preventing and/or treating novel coronavirus pneumonia.